Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P55075
UPID:
FGF8_HUMAN
Alternative names:
Androgen-induced growth factor; Heparin-binding growth factor 8
Alternative UPACC:
P55075; A1A514; Q14915; Q15766
Background:
Fibroblast growth factor 8 (FGF8), also known as Androgen-induced growth factor and Heparin-binding growth factor 8, is pivotal in embryonic development, cell proliferation, differentiation, and migration. It is essential for the normal development of the brain, eyes, ears, limbs, and the gonadotropin-releasing hormone (GnRH) neuronal system.
Therapeutic significance:
FGF8's involvement in Hypogonadotropic hypogonadism 6 with or without anosmia and Hypoplastic femurs and pelvis highlights its potential as a therapeutic target. Understanding FGF8's role could lead to novel treatments for these conditions, emphasizing the importance of research in this area.